These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11367898)

  • 21. Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients.
    Cheng SH; Horng CF; Clarke JL; Tsou MH; Tsai SY; Chen CM; Jian JJ; Liu MC; West M; Huang AT; Prosnitz LR
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1401-9. PubMed ID: 16472935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility of concurrent adjuvant chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer.
    Han S; Kim J; Sohn S; Kwak GH; Kim JY; Park K
    J Surg Oncol; 2007 Jan; 95(1):45-50. PubMed ID: 17192866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?
    Ring A; Webb A; Ashley S; Allum WH; Ebbs S; Gui G; Sacks NP; Walsh G; Smith IE
    J Clin Oncol; 2003 Dec; 21(24):4540-5. PubMed ID: 14673041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
    Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
    Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Papadimitriou CA; Papakostas P; Timotheadou E; Aravantinos G; Bamias A; Fountzilas G
    Cancer Invest; 2008 Jun; 26(5):491-8. PubMed ID: 18568771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Postoperative radiotherapy of the chest wall in patients with male breast cancer].
    Zabel-du Bois A; Milker-Zabel S; Wannenmacher M; Debus J
    Zentralbl Chir; 2007 Oct; 132(5):391-5. PubMed ID: 17907080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using loco-regional recurrence as an indicator of the quality of breast cancer treatment.
    Ernst MF; Voogd AC; Coebergh JW; Poortmans PM; Roukema JA
    Eur J Cancer; 2004 Mar; 40(4):487-93. PubMed ID: 14962713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging modalities for adjuvant therapy of breast cancer: neoadjuvant chemotherapy.
    Ragaz J
    NCI Monogr; 1986; (1):145-52. PubMed ID: 3534588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
    Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
    J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local recurrence in breast cancer after conservative surgery: timing of radiotherapy and sequencing of chemotherapy.
    Donato V; Monaco A; Messina F; De Sanctis V; Messineo D; Banelli E; Maurizi Enrici R
    Anticancer Res; 2004; 24(2C):1303-6. PubMed ID: 15154664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial.
    Groenvold M; Fayers PM; Petersen MA; Mouridsen HT
    Breast Cancer Res Treat; 2006 Aug; 98(3):275-84. PubMed ID: 16541325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer.
    Kumpulainen EJ; Hirvikoski PP; Johansson RT
    Acta Oncol; 2008; 47(1):120-3. PubMed ID: 18097780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study.
    Toledano A; Garaud P; Serin D; Fourquet A; Bosset JF; Breteau N; Body G; Azria D; Le Floch O; Calais G
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):324-32. PubMed ID: 16542788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Recent advance in adjuvant therapy for breast cancer].
    Shimizu C; Watanabe T
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2458-69. PubMed ID: 12506467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
    Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
    J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma.
    Bellon JR; Shulman LN; Come SE; Li X; Gelman RS; Silver BJ; Harris JR; Recht A
    Cancer; 2004 Apr; 100(7):1358-64. PubMed ID: 15042668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.
    Gruber G; Bonetti M; Nasi ML; Price KN; Castiglione-Gertsch M; Rudenstam CM; Holmberg SB; Lindtner J; Golouh R; Collins J; Crivellari D; Carbone A; Thürlimann B; Simoncini E; Fey MF; Gelber RD; Coates AS; Goldhirsch A;
    J Clin Oncol; 2005 Oct; 23(28):7089-97. PubMed ID: 16192592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.